Results 121 to 130 of about 54,797 (163)
Some of the next articles are maybe not open access.
Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design, 2005An effective treatment for age-related cognitive deficits remains an unmet medical need. Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy. This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.
Gregory M, Rose +3 more
openaire +2 more sources
Disaggregatory action of phosphodiesterase inhibitors
Pharmacological Research Communications, 1981Summary Papaverine and three hypotensive xanthines were shown to disaggregate platelet clumps in anaesthetized cats. The order of disaggregatory potency was: IMBX > papaverine > > aminophylline ≫ xantinol nicotinate. This effect was not associated with the release of prostacyclin. It is concluded that disaggregatory action of papaverine and xanthines
M, Radomski, J, Swies, R J, Gryglewski
openaire +2 more sources
Phosphodiesterase inhibitors in airways disease
European Journal of Pharmacology, 2006Phosphodiesterases hydrolyse intracellular cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5' monophosphates, and exist as 11 families. They are found in a variety of inflammatory and structural cells.
openaire +2 more sources
Inhibitors of phosphodiesterases in the treatment of cough
Respiratory Physiology & Neurobiology, 2018A group of 11 enzyme families of metalophosphohydrolases called phosphodiesterases (PDEs) is responsible for a hydrolysis of intracellular cAMP and cGMP. Xanthine derivatives (methylxanthines) inhibit PDEs without selective action on their single isoforms and lead to many pharmacological effects, e.g.
Juraj, Mokry +3 more
openaire +2 more sources
Phosphodiesterase Inhibitors and Cerebral Vasospasm
Archives of Neurology, 1975Experimental cerebral vasospasm was studied in cat and monkey models. In the cat, the basilar artery was exposed by a transclival approach and spasm induced by the application of blood to the vessel. In the monkey, spasm was produced by injecting blood into the subarachnoid space.
E S, Flamm, J, Kim, J, Lin, J, Ransohoff
openaire +3 more sources
Inhibitors of phosphodiesterase as cancer therapeutics
European Journal of Medicinal Chemistry, 2018Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in many physiological processes including visual transduction, cell proliferation and differentiation, cell-cycle regulation, gene expression, inflammation, apoptosis, and metabolic function ...
Ting, Peng +7 more
openaire +2 more sources
[Phosphodiesterase inhibitors].
Annales de cardiologie et d'angeiologie, 1991Phosphodiesterase III inhibitors constitute a new therapeutic group for congestive cardiac failure. They inhibit the degradation of cyclic adenosine monophosphate and increase the intracellular calcium. They have a double inotropic and vasodilator haemodynamics occurs without any increase in the myocardial effect.
A, Sarkis, M, Pornin
openaire +1 more source
The role of phosphodiesterase inhibitors in impotence
Expert Opinion on Investigational Drugs, 1997Penile erection is mediated by nitric oxide (NO) and its second messenger cyclic guanosine monophosphate (cGMP). The activity of cGMP is modulated by the enzyme phosphodiesterase (PDE). The most important physiological isoform of the enzyme in the penis is PDE5.
openaire +2 more sources
Targeting cancer with phosphodiesterase inhibitors
Expert Opinion on Investigational Drugs, 2009For many cancers, there has been a shift from management with traditional, nonspecific cytotoxic chemotherapies to treatment with molecule-specific targeted therapies that are used either alone or in combination with traditional chemotherapy and radiation therapy.
Rajkumar, Savai +6 more
openaire +2 more sources
Phosphodiesterase Inhibitors in Raynaud's Phenomenon
Annals of Pharmacotherapy, 2006Objective: TO evaluate the efficacy of the phosphodiesterase type 5 (PDE5) inhibitors in the treatment of Raynaud's phenomenon. Data Sources: Searches of MEDLINE (1966–March 2006) and Web of Science (1980–March 2006) were conducted ...
openaire +2 more sources